KOLs and Strategic Advisors

Diversifying Risk and Accelerating
Development of Priority Assets

Patricia Lorusso
DO, PhD

  • Professor of medicine (medical oncology)
  • Chief of experimental therapeutics
  • Associate cancer center director for experimental therapeutics
  • Leader of the Phase I disease aligned research team at Yale Cancer Center and Smilow Cancer Hospital

Robert A. Figlin
MD, FACP

  • Steven Spielberg Family Chair in Hematology Oncology
  • Professor of Medicine and Biomedical Sciences Director
  • Division of Hematology Oncology Deputy Director Samuel Oschin Comprehensive Cancer Institute Cedars-Sinai Medical Center

Howard Soule
PhD

  • Prostate Cancer Foundation Global Research Strategies
  • Member of the Department of Defense Prostate Cancer Research Program Integration Panel
  • Managing Director of Knowledge Universe Health and Wellness Group

Scott Tagawa
MD, MS, FACP, FASCO

  • Professor of Medicine and Urology, Medical Director of the Genitourinary Oncology Research Program, Weill Cornell Medicine (WCM); Leader of GU, co-lead of Experimental Therapeutics Program of the Meyer Cancer Center
  • WCM PI for the Alliance for Clinical Trials in Oncology

Llew Keltner
MD, PhD

  • CEO, EPISTAT, CEO, AgonOx, a biotech company developing OX40 agonists for use in cancer therapy
  • Previous President of Novici Biotech, a privately-held gene and protein optimization firm
  • CEO and President of Light Sciences Oncology

Rakesh Dixit
PhD

  • President and CEO of Bionavigen
  • 30+ years as inventor and scientist with top pharma: Merck, Johnson & Johnson, Medimmune, AstraZeneca
  • Winner of prestigious “Long-Standing Contributions to the ADC Field” award by ADC Review Journal of Antibody Drug-Conjugates

Kevin Heller
MD

  • 20+ years as physician-scientist, and oncology drug developer
  • Previous biopharma roles include: CMO, Tallac Therapeutics; EVP, R&D , Jasper Therapeutics; CMO, NextCure, VP, Head Antibody Clinical Dev, Incyt; Senior Medical Director, AZ; Global Lead, Oncology, BMS

Josh Lang
MD, MS

  • Division of Hematology, Medical Oncology and Palliative Care, UW
  • Lead PI for Department of Defense Prostate Cancer Research Program, PI of Prostate Cancer Foundation-funded project to investigate therapeutic targeting of AR-variant prostate cancer with a novel ADC